How the Discovery of TNF-α Has Advanced Gastrointestinal Diseases and Treatment Regimes

St‐Pierre, Joëlle; Chadee, Kris

doi:10.1007/s10620-014-3042-5

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of TNF inhibitors has been validated as a suitable treatment for IBD. 17 However, a small number of patients with IBD have been known to develop treatment-related tuberculosis even after screening and adequate treatment for LTBI. 7 8 18 To the best of our knowledge, this was the first study to compare the incidence of active tuberculosis in patients with IBD with different LTBI status within 1 year after the initiation of TNF inhibitor treatment.…”

Section: Discussionmentioning

confidence: 99%

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease

et al. 2018

View full text Add to dashboard Cite

BackgroundWe investigated the incidence of active tuberculosis among patients with inflammatory bowel disease (IBD) treated with tumor necrosis factor (TNF) inhibitors, with or without latent tuberculosis infection (LTBI).MethodsThe study was performed at a Korean tertiary referral center between January 2011 and June 2017. In total, 740 patients with IBD who underwent LTBI screening tests and were followed-up for ≥ 1 year after TNF inhibitor treatment initiation were enrolled. LTBI was detected on the basis of tuberculin skin test results, interferon-gamma release assay results, chest X-ray findings, and previous tuberculosis treatment history. The patients were classified into LTBI (n = 84) or non-LTBI (n = 656) group. The risk of developing tuberculosis in each group was assessed on the basis of standardized incidence ratio (SIR) and 95% confidence interval (CI) for active tuberculosis.ResultsMean patient age was 33.1 years, and patients with Crohn's disease were predominant (80.7%). Within 1 year after the initiation of TNF inhibitor treatment, 1 patient in the LTBI group (1/84; 1.2%) and 7 patients in the non-LTBI group (7/656; 1.1%) developed active tuberculosis. The overall 1-year incidence of tuberculosis among the patients was significantly higher than that among the general population (SIR, 14.0; 95% CI, 7.0–28.0), and SIR was not affected by LTBI status (LTBI group: 14.5, 95% CI, 2.0–102.6; non-LTBI group: 14.0, 95% CI, 6.7–29.4).ConclusionPatients with IBD undergoing TNF inhibitor treatment showed a higher 1-year incidence of tuberculosis than the general population irrespective of LTBI status.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In this sense, MeJA and its analogues have the potential to inhibit TNF production in murine macrophage and HCAT keratinocyte cells . To date, in clinical practice, only antibody therapy has been found to be an efficient method of neutralizing the effects of TNF in patients with chronic inflammatory conditions such as IBDs …”

Section: Meja: a Potential Phytohormone For Anti‐tnf Therapy In The Tmentioning

confidence: 99%

“…[71] To date, in clinical practice, only antibody therapy has been found to be an efficient method of neutralizing the effects of TNF in patients with chronic inflammatory conditions such as IBDs. [72] The first hypothesis is based on the possible therapeutic potential of MeJA in the modulation of IBDs, suggesting an anti-regulatory mechanism, based on the reduction of the expression of TNF tissue levels, minimizing apoptosis in the intestinal crypts with a direct effect on the apoptotic extrinsic pathway. TNF acts as a major pro-inflammatory cytokine in pathway signalling.…”

Section: Intestinal Apoptosismentioning

confidence: 99%

Methyl jasmonate: a phytohormone with potential for the treatment of inflammatory bowel diseases

Besson

Picoli

Matioli

et al. 2018

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives The phytohormone methyl jasmonate (MeJA) has been identified as a vital cell regulator in plants. This substance is analogous to eicosanoids and similar to that of anti-inflammatory prostaglandins. In animals and in animal cells, it displayed an efficient neuroprotective, anti-inflammatory and antioxidant action; while in tumoral strains, it demonstrates a potentially highly attractive mechanism of apoptosis induction through various cellular and molecular mechanisms. The aim of the present review was to explore two new hypotheses that explain the action of MeJA, a lipid phytohormone and its potentially anti-apoptotic mechanism for use as a therapeutic target for future treatment of Inflammatory bowel diseases (IBDs). Key findings Methyl jasmonate is a new candidate for the treatment of IBDs, modulating the expression of the major classes of caspase-type protease families that selectively act on the extrinsic and intrinsic pathways of the apoptotic process. Its action is based on the reduction of the expression in tumour necrosis factor tissue levels and the modulating action of reactive oxygen species production, acting only on the destruction of cells that express the diseased phenotype, and preserving cells that are not transformed. Conclusions Methyl jasmonate may represent an alternative for the transduction processes of important signals in the cellular renewal of the intestinal mucosa.

show abstract

“…TNF-α is a principal mediator of the acute inflammatory response, and has been previously associated with IBD and several other immunedriven disorders. Currently, anti-TNF treatments are already in use to treat IBD and other GI disorders [254,255].…”

Section: Tnfrsf1a: Tnf Receptor Superfamily Member 1amentioning

confidence: 99%

Exome Sequencing in Gastrointestinal Food Allergy Induced by Multiple Food Protein

Juan¹

View full text Add to dashboard Cite

show abstract

How the Discovery of TNF-α Has Advanced Gastrointestinal Diseases and Treatment Regimes

Cited by 4 publications

References 34 publications

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease

Methyl jasmonate: a phytohormone with potential for the treatment of inflammatory bowel diseases

Exome Sequencing in Gastrointestinal Food Allergy Induced by Multiple Food Protein

Contact Info

Product

Resources

About